Research programme: antibody therapeutics - Well Marker Bio
Alternative Names: WM A1Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Well Marker Bio
- Developer Wellmarker Bio
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastric cancer; Liver cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Liver-cancer in South Korea (Parenteral)
- 28 Apr 2024 No recent reports of development identified for research development in Gastric-cancer in South Korea (Parenteral)
- 10 Mar 2020 Early research in Gastric cancer in South Korea (Parenteral), before March 2020